-+ 0.00%
-+ 0.00%
-+ 0.00%

On December 11, Boehringer Ingelheim China announced that China's State Drug Administration approved Boyouwei® for the treatment of advanced pulmonary fibrosis in adults. Following recent approval in the US and China for the treatment of idiopathic pulmonary fibrosis, PPF is the second indication approved for namistel.

Zhitongcaijing·12/11/2025 00:09:03
Listen to the news
On December 11, Boehringer Ingelheim China announced that China's State Drug Administration approved Boyouwei® for the treatment of advanced pulmonary fibrosis in adults. Following recent approval in the US and China for the treatment of idiopathic pulmonary fibrosis, PPF is the second indication approved for namistel.